Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape

被引：121
|
作者：
Upadhaya, Samik [1 ]
Neftelinov, Svetoslav T. [2 ]
Hodge, Jeffrey [2 ]
Campbell, Jay [1 ]
机构：
[1] Canc Res Inst, New York, NY 10006 USA
[2] IQVIA, Durham, NC USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 07期
关键词：
D O I：
10.1038/d41573-022-00030-4
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：482 / 483
页数：2
相关论文
共 50 条
  • [1] Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
    Samik Upadhaya
    Svetoslav T. Neftelinov
    Jeffrey Hodge
    Jay Campbell
    Nature Reviews Drug Discovery, 2022, 21 : 482 - 483
  • [2] The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
    Jun Tang
    Jia Xin Yu
    Vanessa M. Hubbard-Lucey
    Svetoslav T. Neftelinov
    Jeffrey P. Hodge
    Yunqing Lin
    Nature Reviews Drug Discovery, 2018, 17 : 854 - 855
  • [3] The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
    Tang, Jun
    Yu, Jia Xin
    Lin, Yunqing
    NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (12) : 854 - 854
  • [4] TRIAL WATCH Combinations take centre stage in PD1/PDL1 inhibitor clinical trials
    Upadhaya, Samik
    Neftelino, Svetoslav T.
    Hodge, Jeffrey P.
    Oliva, Cristina
    Campbell, Jay R.
    Yu, Jia Xin
    NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (03) : 168 - 169
  • [5] Combinations take centre stage in PD1/PDL1 inhibitor clinical trials
    Samik Upadhaya
    Svetoslav T. Neftelino
    Jeffrey P. Hodge
    Cristina Oliva
    Jay R. Campbell
    Jia Xin Yu
    Nature Reviews Drug Discovery, 2021, 20 : 168 - 169
  • [6] PD1/PDL1 Biomarker Strategies
    Brambilla, Elisabeth
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S126 - S127
  • [7] PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx
    Ana Rosa Saez-Ibañez
    Erin Sommers
    Samik Upadhaya
    Jay Campbell
    Nature Reviews Drug Discovery, 2023, 22 : 944 - 945
  • [8] PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx
    Saez-Ibanez, Ana Rosa
    Sommers, Erin
    Upadhaya, Samik
    Campbell, Jay
    NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (12) : 944 - 945
  • [9] Clinical Significance of PD1 and PDL1 in Human Breast Cancer
    Uhercik, Michal
    Sanders, Andrew J.
    Owen, Sioned
    Davies, Eleri L.
    Sharma, Anup K.
    Jiang, Wen G.
    Mokbel, Kefah
    ANTICANCER RESEARCH, 2017, 37 (08) : 4249 - 4254
  • [10] Resistance to PD1/PDL1 checkpoint inhibition
    O'Donnell, Jake S.
    Long, Georgina V.
    Scolyer, Richard A.
    Teng, Michele W. L.
    Smyth, Mark J.
    CANCER TREATMENT REVIEWS, 2017, 52 : 71 - 81
12345